Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Supplies
SectorN/A
Phone+1-781-6473900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Alere (NYSE:ALR) Frequently Asked Questions
What is Alere's stock symbol?
Alere trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALR."
How were Alere's earnings last quarter?
Alere Inc (NYSE:ALR) issued its quarterly earnings results on Friday, November, 4th. The medical research company reported $0.19 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.54 by $0.35. The medical research company earned $582 million during the quarter, compared to analysts' expectations of $605.50 million. Alere's revenue was down 3.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.10) earnings per share. View Alere's Earnings History.
Has Alere been receiving favorable news coverage?
News articles about ALR stock have trended positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Alere earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future.
Who are Alere's key executives?
Alere's management team includes the folowing people:
- Gregg J. Powers, Independent Chairman of the Board
- Namal Nawana, President, Chief Executive Officer, Director
- James F. Hinrichs, Chief Financial Officer, Executive Vice President
- Daniella Cramp, Global President - Cardiometabolic Business Unit
- Sanjay Malkani, Global President - Toxicology
- Avi Pelossof, Global President - Infectious Disease Business Unit
- Ellen Chiniara J.D., Senior Vice President, General Counsel, Chief Ethics and Compliance Officer, Secretary
- Robert Hargadon, Senior Vice President - Global Human Resources
- John Bridgen Ph.D., Senior Vice President - Business Development
- Mark Gladwell, Senior Vice President - Global Operations
What is Alere's stock price today?
One share of ALR stock can currently be purchased for approximately $2.50.
What is Alere's official website?
How can I contact Alere?
Alere's mailing address is 51 Sawyer Rd Ste 200, WALTHAM, MA 02453-3448, United States. The medical research company can be reached via phone at +1-781-6473900.
MarketBeat Community Rating for Alere (NYSE ALR)
MarketBeat's community ratings are surveys of what our community members think about Alere and other stocks. Vote "Outperform" if you believe ALR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALR will underperform the S&P 500 over the long term. You may vote once every thirty days.
